Among the 13 FDA approvals during the second quarter of 2021, one has undoubtedly been the biggest talking point. Biogen’s Alzheimer disease drug Aduhelm (aducanumab) has become one of the most  controversial authorizations for some time, with much debate about whether the FDA…

Para acessar a publicação na íntegra clique aqui

Fonte: 578 | August 2021 | volume 20 www.nature.com/nrd